Showing results (51-60 of 60) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 60 results.
Nutrition, Metabolism, and Cardiovascular Diseases : NMCD|June 6, 2026
Effect of add-on PCSK9 inhibitors on endocan and arterial stiffness in heterozygous familial hypercholesterolemia: a two-lipid center real-world studyArianna Toscano, Giosiana Bosco, Francesco Di Giacomo Barbagallo, et al.
Biomedicines|June 2, 2021
Endocan and Circulating Progenitor Cells in Women with Systemic Sclerosis: Association with Inflammation and Pulmonary HypertensionAlberto Lo Gullo, Giuseppe Mandraffino, Javier Rodríguez-Carrio, et al.
Biomedicines|August 27, 2021
Expression and Change of miRs 145, 221 and 222 in Hypertensive Subjects Treated with Enalapril, Losartan or OlmesartanGiuseppe Mandraffino, Alberto Lo Gullo, Maria Cinquegrani, et al.
Biomolecules|April 23, 2022
PCSK9 Plasma Levels Are Associated with Mechanical Vascular Impairment in Familial Hypercholesterolemia Subjects without a History of Atherosclerotic Cardiovascular Disease: Results of Six-Month Add-On PCSK9 Inhibitor TherapyArianna Toscano, Maria Cinquegrani, Michele Scuruchi, et al.
Atherosclerosis|January 29, 2017
Biglycan expression, earlier vascular damage and pro-atherogenic profile improvement after smoke cessation in young peopleGiuseppe Mandraffino, Caterina Oriana Aragona, Michele Scuruchi, et al.
Clinical Science (London, England : 1979)|January 19, 2017
BAY 11-7082 inhibits the NF-κB and NLRP3 inflammasome pathways and protects against IMQ-induced psoriasisNatasha Irrera, Mario Vaccaro, Alessandra Bitto, et al.
Plos One|March 17, 2017
Circulating progenitor cells in hypertensive subjects: Effectiveness of a treatment with olmesartan in improving cell number and miR profile in addition to expected pharmacological effectsGiuseppe Mandraffino, Caterina Oriana Aragona, Valentina Cairo, et al.
Journal of Clinical Lipidology|March 1, 2020
Arterial stiffness improvement after adding on PCSK9 inhibitors or ezetimibe to high-intensity statins in patients with familial hypercholesterolemia: A Two-Lipid Center Real-World ExperienceGiuseppe Mandraffino, Roberto Scicali, Javier Rodríguez-Carrio, et al.
Biomedicines|July 27, 2022
Fatty Liver as Potential Biomarker of Atherosclerotic Damage in Familial Combined HyperlipidemiaGiuseppe Mandraffino, Carmela Morace, Maria Stella Franzè, et al.
Molecular and Cellular Biochemistry|February 13, 2017
Clinical impact of angiotensin I converting enzyme polymorphisms in subjects with resistant hypertensionEgidio Imbalzano, Marco Vatrano, Sebastiano Quartuccio, et al.
Pageof 6